GlassScriptPhysician profile
Erica J Leventhal
NPI 1972562353
$1,004.88
in general payments reported to CMS, 2019-2025
12 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2021: $79.91 · 2022: $165 · 2023: $309 · 2024: $21.42 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.77 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $232.03 | 2023-2025 | Slynd, Twirla |
| Astellas Pharma US INC | $218.74 | 2023-2024 | Veozah |
| Minerva Surgical, INC | $164.76 | 2022 | |
| Hologic Sales and Service, LLC | $101.28 | 2019-2021 | |
| Abbvie INC. | $98.61 | 2019 | |
| Allergan, INC. | $80.87 | 2019 | |
| Therapeuticsmd, INC. | $34.14 | 2019 | |
| Coopersurgical, INC. | $21.32 | 2019 | |
| Avion Pharmaceuticals | $15.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.81 | 2019 | |
| Duchesnay USA Incorporated | $12.40 | 2019 | |
| Millicent US INC | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Leventhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.